Strong Phosphate Sales Volumes
Sold 1.9 million tons of phosphate in Q1 — the highest quarterly phosphate sales volume in five years; finished-product quarterly capability target previously 1.8–2.0 million tons.
Improved U.S. Phosphoric Acid Operating Rates
Bartow, Riverview and Faustina ran at or above ~80% phosphoric acid operating rates in Q1 (in line with targets); New Wales completed a large planned turnaround improving future production capability.
Potash Market Strength
Potash fundamentals remain balanced with robust demand across major markets; Canpotex committed through June and on pace for a record 2026; Belle Plaine and Esterhazy production/mix improved and Hydroflow ramp expected to lower costs.
Favorable Q1 Sulfur Cost and Stripping Margins (Q1)
Average realized sulfur cost in Q1 was $379/ton enabling stripping margins near ~$400/ton for the quarter on the company’s sales book.
Portfolio Optimization and Capital Discipline
Reduced 2026 CapEx by $250 million to $1.25 billion; sold Carlsbad potash mine and three mines, idled underperforming assets; instituted workforce reductions expected to generate $50 million annualized expense savings ( ~$15 million realized in 2026).
Working Capital / Inventory Actions
Moved inventory built at end of 2025 into sales position; phosphate finished goods inventory declined by roughly $120 million in Q1; company reiterates working capital release target of $300–$500 million.
Mosaic Biosciences Growth
Biosciences business growing rapidly: two product launches in Q1, company expects 8–10 new product launches in 2026 and expects Mosaic Biosciences revenues to double again in 2026.
Raw-material and Supply Advantages
Approximately 80% of U.S. ammonia needs met by internal plant and below-market domestic agreements; roughly 80% of sulfur needs sourced from U.S. Gulf refineries in molten form — structural supply/contract advantages versus many peers.